The Ipamorelin and CJC 1295 dosage protocol is built on two complementary GH pathways that amplify each other. Here is the mechanistic reason this combination dominates growth hormone research.
The Ipamorelin and CJC 1295 dosage protocol has become the standard reference point for GH secretagogue research because these two compounds activate growth hormone release through completely different receptor pathways — and those two pathways are additive when stimulated simultaneously. This is not a redundant combination. It is a mechanistically designed amplification of the natural GH pulse.
Understanding why they work together requires a clear picture of how each compound reaches the pituitary and what signal it sends when it gets there.
Endogenous growth hormone secretion is pulsatile. The pituitary releases GH in discrete bursts — primarily during deep sleep and in response to exercise and fasting — and these pulses are governed by two opposing hypothalamic signals: GHRH (growth hormone releasing hormone), which triggers GH secretion, and somatostatin, which suppresses it. Natural GH pulses occur when GHRH signal peaks and somatostatin signal is simultaneously low.
CJC-1295 without DAC (Mod GRF 1-29) is a GHRH analogue. It binds to GHRH receptors on pituitary somatotrophs and triggers the same GH release signal as endogenous GHRH. With a half-life of approximately 30 minutes, it produces a sharp, short-duration GH release signal that mirrors the natural pulsatile pattern.
Ipamorelin operates through the ghrelin receptor (GHS-R) — a completely separate pathway. It is a selective growth hormone secretagogue that stimulates GH release through the ghrelin axis without the off-target effects on cortisol and prolactin that older GHRPs (like GHRP-6 and GHRP-2) produce. Ipamorelin receptor research published in the European Journal of Endocrinology established that Ipamorelin's selectivity for the GH axis distinguishes it from earlier secretagogues, producing clean GH release without meaningful cortisol or prolactin stimulation.
When both compounds are administered together, the GHRH pathway (CJC-1295) and the ghrelin pathway (Ipamorelin) stimulate the pituitary simultaneously via different receptor systems. The result is a GH pulse that research models have shown to be substantially larger than either compound produces alone — the "loaded gun, pulled trigger" dynamic that makes this combination so consistent in research outcomes.
One of the reasons Ipamorelin specifically — rather than other GHRPs — became the standard pairing for CJC-1295 is its cortisol profile. GHRP-6 and GHRP-2, earlier ghrelin receptor agonists, produce significant cortisol and prolactin elevation alongside GH release. In research models designed to study GH-axis effects specifically, cortisol co-elevation is a confounding variable that complicates interpretation of results.
Ipamorelin's selectivity for the GH axis means it does not meaningfully elevate cortisol or prolactin at standard research doses. This makes the CJC-1295/Ipamorelin combination a cleaner research tool — the GH signal is amplified without introducing cortisol-mediated catabolism or prolactin-related variables into the study. For research programs where GH-axis specificity matters, this selectivity is not a minor detail.
The cortisol-sparing profile also makes the combination more useful for research programs studying longer-duration GH effects, where repeated cortisol spikes from less selective secretagogues would accumulate into a significant confound over weeks of study.
In research models, the CJC-1295 and Ipamorelin combination is most commonly studied at a 1:1 ratio by mass — equal parts of each compound administered simultaneously. The pre-blended 10mg format (5mg CJC-1295 No DAC + 5mg Ipamorelin) provides this ratio in a single vial, simplifying reconstitution and ensuring consistent compound ratios across all administrations in a study protocol.
Standard reconstitution uses bacteriostatic water. The typical research approach administers the blend in a single subcutaneous injection, timed to coincide with periods of low endogenous somatostatin signaling — which in animal models mirrors the pre-sleep or fasted states where natural GH pulsatility is highest. This timing alignment with natural GH rhythms is a consistent feature of well-designed pulsatile GH research protocols.
CJC-1295 with DAC is not used for this combination in pulsatile research — the sustained albumin-binding half-life of the DAC version blunts the pulse and converts the GH release pattern from pulsatile to continuous, which defeats the mechanistic premise of the stack. The No DAC version is the correct choice whenever GH pulse dynamics are part of the research question.
Beyond Health Lab supplies the CJC-1295 Ipamorelin Blend 10mg at ≥99% verified purity across the combined formulation, confirmed by independent HPLC and mass spectrometry with a Certificate of Analysis on every lot. The pre-blended format ensures the 1:1 ratio is consistent across every vial in a research run.
Join 10,000+ researchers. Get your discount code, early access to new compounds, and protocol insights.
No spam, ever. Unsubscribe anytime.
Check your inbox for your discount code.
Here's a preview:
Valid on all products · Single use
